Literature DB >> 19789327

Inhibiting the hypoxia response for cancer therapy: the new kid on the block.

Mei Yee Koh1, Taly R Spivak-Kroizman, Garth Powis.   

Abstract

The hypoxia-inducible transcription factor (HIF)-1alpha inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here, we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with other promising HIF-1alpha inhibitors.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19789327      PMCID： PMC2760048          DOI： 10.1158/1078-0432.CCR-09-1650

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.

Authors:  Chalet Tan; Rita G de Noronha; Anthony J Roecker; Beata Pyrzynska; Fatima Khwaja; Zhaobin Zhang; Huanchun Zhang; Quincy Teng; Ainsley C Nicholson; Paraskevi Giannakakou; Wei Zhou; Jeffrey J Olson; M Manuela Pereira; K C Nicolaou; Erwin G Van Meir
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

2.  A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}.

Authors:  Shan Hua Li; Dong Hoon Shin; Yang-Sook Chun; Myung Kyu Lee; Myung-Suk Kim; Jong-Wan Park
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

3.  Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.

Authors:  Mei Y Koh; Taly Spivak-Kroizman; Sara Venturini; Sarah Welsh; Ryan R Williams; D Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2008-01       Impact factor: 6.261

4.  Identification of a novel small molecule HIF-1alpha translation inhibitor.

Authors:  Takuhito Narita; Shaoman Yin; Christine F Gelin; Carlos S Moreno; Manuel Yepes; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

5.  Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival.

Authors:  Bryan C Barnhart; Jennifer C Lam; Regina M Young; Peter J Houghton; Brian Keith; M Celeste Simon
Journal:  Cancer Biol Ther       Date:  2008-09-11       Impact factor: 4.742

6.  Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.

Authors:  Annamaria Rapisarda; Jessica Zalek; Melinda Hollingshead; Till Braunschweig; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Stephen M Hewitt; Robert H Shoemaker; Giovanni Melillo
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

7.  The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.

Authors:  Sarah J Welsh; Ryan R Williams; Anne Birmingham; David J Newman; D Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2003-03       Impact factor: 6.261

Review 8.  Hypoxia: a key regulator of angiogenesis in cancer.

Authors:  Debbie Liao; Randall S Johnson
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264
  8 in total
  12 in total

1.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

2.  Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells.

Authors:  Tzyh-Chyuan Hour; Yan-Liang Lai; Ching-I Kuan; Chen-Kung Chou; Ju-Ming Wang; Huang-Yao Tu; Huei-Ting Hu; Chang-Shen Lin; Wen-Jeng Wu; Yeong-Shiau Pu; Esta Sterneck; A-Mei Huang
Journal:  Biochem Pharmacol       Date:  2010-04-10       Impact factor: 5.858

3.  HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Natsumi Irahara; Andrew T Chan; Jeffrey A Meyerhardt; Daniel C Chung; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

4.  Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.

Authors:  Han Zhang; Zheng Chen; Roberto N Miranda; L Jeffrey Medeiros; Nami McCarty
Journal:  Blood       Date:  2017-06-07       Impact factor: 22.113

5.  A Novel Hypoxia-inducible Factor 1α Inhibitor KC7F2 Attenuates Oxygen-induced Retinal Neovascularization.

Authors:  Xiaoyu Tang; Kaixuan Cui; Xi Lu; Peiqi Wu; Shanshan Yu; Boyu Yang; Yue Xu; Xiaoling Liang
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

6.  Hypoxia-specific targets in cancer therapy: role of splice variants.

Authors:  Dirk Vordermark
Journal:  BMC Med       Date:  2010-07-12       Impact factor: 8.775

Review 7.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Authors:  Woonyoung Choi; Bogdan Czerniak; Andrea Ochoa; Xiaoping Su; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Nat Rev Urol       Date:  2014-06-24       Impact factor: 14.432

8.  Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.

Authors:  Haitao Wang; Carter Lindborg; Vitali Lounev; Jung-Hoon Kim; Ruth McCarrick-Walmsley; Meiqi Xu; Laura Mangiavini; Jay C Groppe; Eileen M Shore; Ernestina Schipani; Frederick S Kaplan; Robert J Pignolo
Journal:  J Bone Miner Res       Date:  2016-04-20       Impact factor: 6.741

9.  Hypoxia-inducible factor-1α mRNA: a new target for destabilization by tristetraprolin in endothelial cells.

Authors:  Sandrine Chamboredon; Delphine Ciais; Agnès Desroches-Castan; Pierre Savi; Françoise Bono; Jean-Jacques Feige; Nadia Cherradi
Journal:  Mol Biol Cell       Date:  2011-07-20       Impact factor: 4.138

10.  Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas.

Authors:  Monika Golinska; Helen Troy; Yuen-Li Chung; Paul M McSheehy; Manuel Mayr; Xiaoke Yin; Lucy Ly; Kaye J Williams; Rachel E Airley; Adrian L Harris; John Latigo; Meg Perumal; Eric O Aboagye; David Perrett; Marion Stubbs; John R Griffiths
Journal:  BMC Cancer       Date:  2011-05-25       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.